https://www.technologynetworks.com/drug-discovery/news/transmolecular-receives-orphan-drug-designation-for-131itm601-for-the-treatment-of-melanoma-212317
The drug candidate is currently in a Phase 1/2 clinical trial for the treatment of recurrent malignant melanoma.
orphan drug designationtransmolecularreceives